Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onapristone in PR-Expressing Cancers
NCT02052128Phase 2Unknown
- Sponsor
- Arno Therapeutics, Inc.
- Start
- Jan 2014
- Primary completion
- Oct 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of onapristone extended release in uterine endometrioid adenocarcinoma (EC), ovarian cancer, breast cancer and 1 more (6 arms), sponsored by Arno Therapeutics, Inc. Primary endpoints: Recommended Phase 2 Dose at 57 days and Overall Response Rate. Status: unknown.
02
Drugs
onapristone extended release
03
Conditions
uterine endometrioid adenocarcinoma (EC)ovarian cancerbreast canceruterine sarcoma
Beyond the preview
Go deeper on NCT02052128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052128.